Skip to main content

Voquezna

Pronunciation: voe-kwez-nah
Generic name: vonoprazan
Dosage form: oral tablet
Drug class: Proton pump inhibitors

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 2, 2023.

What is Voquezna?

Voquezna (vonoprazan) is an oral potassium-competitive, acid blocker that may be used to block acid production in the stomach and is approved for the:

Voquezna works by inhibiting the potassium-dependant component of the H+, K+-ATPase enzyme system (also called the acid [proton] pump) within the parietal cell, blocking the final step of acid production. Voquezna does not require acid to activate it, concentrates in parietal cells, and binds reversibly and non-covalently to the pump. It suppresses both basal and stimulated gastric acid secretion.

Voquezna was first FDA approved on May 3, 2022 as Voquezna Triple and Dual Pak.

Warnings

Do not take Voquezna if you are allergic to Voquezna, vonoprazan, or any of the ingredients in the tablets.

Certain medications that are used to treat HIV-1 may interact with Voquezna and they should not be used together. Tell your healthcare provider about all the medications you take.

May mask the symptoms of gastric cancer. Your healthcare provider should consider additional follow-up and diagnostic testing to rule out gastric cancer.

May cause acute tubulointerstitial nephritis, a type of acute kidney injury.

May increase the risk of Clostridioides difficile-Associated Diarrhea (CDAD) and increase the risk of osteoporosis-related fractures. Voquezna should be taken for the shortest duration appropriate to the condition.

Associated with an increased risk of severe skin conditions including severe cutaneous adverse reactions.

Long-term use may lead to malabsorption or deficiency of Vitamin B12 (Cobalamin), low magnesium levels, or fundic gland polyps.

Before taking

Before taking Voquezna, tell your healthcare provider about all of your medical conditions, including if you:

Pregnancy and breastfeeding

It is not known if Voquezna will harm an unborn baby. Call the Phathom Pharmaceuticals, Inc. Adverse Event reporting line at 1-888- 775-7428 if you inadvertently become pregnant while taking it.

It is not known if Voquezna passes into your breast milk. You and your healthcare provider should decide if you will take it or breastfeed. You should not do both.

How should I take Voquezna?

Take Voquezna exactly as your healthcare provider tells you to take it.

Dosage

Erosive esophagitis

Treatment of H. pylori Infection

What happens if I miss a dose?

Erosive esophagitis

If you miss a dose of Voquezna, take it as soon as possible if it is within 12 hours of the missed dose. If more than 12 hours have passed, skip the missed dose and take the next dose at the regularly scheduled time.

H. pylori infection

If you miss a dose of Voquezna, take it as soon as possible if it is within 4 hours of the missed dose. If more than 4 hours have passed, skip the missed dose and take the next dose at the regularly scheduled time. Continue your regular dosing schedule until the treatment is completed.

What happens if I overdose?

Call your healthcare provider or the Poison Help line at 1-800-222-1222.

What are the side effects of Voquezna?

Voquezna may cause serious side effects, including:

The most common side effects of Voquezna when used for erosive esophagitis affecting 2% to 3% or more people include:

The most common side effects of Voquezna when used with antibiotics for treatment of H. pylori infection affecting 2% or more people include:

These are not all the possible side effects of Voquezna. You may report side effects to the FDA at 1-800-FDA-1088.

What other drugs will affect Voquezna?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Voquezna may affect how other medicines work and other medicines may affect how it works. Tell your doctor if you take:

May interfere with investigations for gastrinoma or neuroendocrine tumors. Temporarily stop Voquezna at least 14 days before assessing chromogranin A (CgA) levels or performing a secretin stimulation test.

See the product information for a full list of interactions.

Storage

Store at room temperature between 68°F to 77°F (20°C to 25°C).

Keep out of the reach of children.

Ingredients

Active: vonoprazan

Inactive: ascorbic acid, croscarmellose sodium, ferric oxide red (only in 20 mg tablets), ferric oxide yellow (only in 10 mg tablets), fumaric acid, hydroxypropyl cellulose, hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol 8000, and titanium dioxide.

Available in 10mg and 20mg tablets.

Manufacturer

Phathom Pharmaceuticals, Inc.

References

  1. Product Label

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.